An Alabama cancer patient recently filed a Taxotere lawsuit alleging the cancer treatment caused permanent hair loss problems.

The plaintiff, Cynthia G., began treatment with doses of Taxotere around July 1, 2014, and continued this treatment through June 2015.

However, after Cynthia underwent treatment with Taxotere, the hair she during treatment (a common and well-known side effect of chemotherapy treatments) never grew back, leaving her with permanent hair loss.

Cynthia filed her Taxotere permanent hair loss lawsuit on March 31, 2017. Defendants named in the complaint include the manufacturers of the Taxotere brand, as well as a number of other drug sponsors, manufacturers, and distributors.

The permanent hair loss lawsuit was filed on multiple counts, including failure to warn, negligence, fraudulent misrepresentation and concealment as well as breach of express warranty.

Background of Taxotere

Taxotere, also known by its generic name, docetaxel, is a chemotherapy drug manufactured by pharmaceutical giant Sanofi Aventis. It is one of the most commonly used breast cancer drugs,

Taxotere is also used to treat lung cancer. It was first approved by the U.S. Food and Drug Administration (FDA) in 1996, and has grown steadily more popular over the years.

Cancer cells are known for the ability to rapidly spread. In order to fight cancer, Taxotere prevents cancer cells from growing which prevents cancer’s rapid spread.

However, it may be that the same function of Taxotere that works to prevent the growth of cancer cells may also prevent the growth of a patient’s hair after chemotherapy treatment is over.

Hair loss is the most well-known side effect of cancer treatment, and patients go into chemotherapy knowing about this complication. However, they generally expect that their hair will grow back after chemotherapy treatment is over.

Unfortunately, many patients treated with Taxotere are discovering that they have difficulty growing their hair back after they finish with treatment. Some even report permanent hair loss problems.

According to this permanent hair loss lawsuit and others like it, Sanofi either knew or should have known that their drug Taxotere was linked with permanent hair loss complications.

Plaintiffs allege that the company not only failed to adequately warn about this risk, but even actively concealed information, instead promoting the drug as both safe and effective. These former patients claim that Sanofi has been aware of reports and studies linking Taxotere to permanent hair loss after chemotherapy since as far back as its approval in 1996.

Filing a Taxotere Permanent Hair Loss Lawsuit

If you or someone you love has suffered from permanent hair loss after cancer treatment with Taxotere, you may be able to gain some kind of financial compensation by joining Taxotere permanent hair loss litigation.

Filing a Taxotere lawsuit cannot take away the pain and suffering a cancer patient endures or take away the effects of permanent hair loss, but it can help compensate for the financial expenses incurred by cancer treatment bills or even lost wages.

The Taxotere Permanent Hair Loss Lawsuit is case no. 2:17-cv-005012-KDE-MBN, in the U.S. District Court for the Eastern District of Louisiana.